Targeted Cell Therapies is pioneering a novel technology platform that enables the conversion of injectable biologics into oral biotherapeutics, addressing significant challenges in drug delivery. This innovative approach allows for the oral administration of large therapeutic molecules, which traditionally require injections or infusions, thus enhancing patient compliance and reducing the associated costs and disruptions to daily life. The technology leverages yeast-derived purified glucan particles (GP) that encapsulate therapeutic payloads, such as nucleic acids or proteins. Upon oral ingestion, these particles are efficiently absorbed by macrophages in the small intestine, which then transport the active therapeutics to sites of inflammation or disease.

The company is actively developing a diverse pipeline of applications targeting various medical conditions, including Gaucher Disease and other lysosomal disorders, inflammatory conditions, low bone density, and metastatic lytic bone disease. By focusing on the oral delivery of therapeutics, Targeted Cell Therapies aims to improve treatment outcomes while minimizing adverse side effects and manufacturing complexities associated with traditional injectable therapies. This strategic focus positions the company to potentially transform the landscape of biopharmaceuticals, making advanced treatments more accessible and manageable for patients.

United States

Targeted Cell Therapies is an early-stage Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. Targeted Cell Therapies  technology permits the oral delivery of large molecules, avoiding the usual need for injection.

Targeted Cell Therapies

Company Details